Patient Protection and Affordable Care Act2024-06-27T20:55:45+00:00
601, 2026

Medispend and RLDatix Life Sciences Complete Merger, Uniting Under the Medispend Brand to Create The Leading Life Sciences Compliance Software-as-a-Service Provider

By |January 6th, 2026|News|

PORTSMOUTH, Jan. 6, 2026 – Medispend and RLDatix Life Sciences today announced the successful completion of their merger, creating a unified organization that will operate under the Medispend name. The combined company offers a comprehensive suite of enterprise software and services for global regulatory and commercial compliance, medical affairs, field enablement and revenue management solutions [...]

312, 2025

State Price Transparency Solution Summary Download

By |December 3rd, 2025|Resources|

Download our State Price Transparency Solution summary to see how MediSpend helps life sciences teams simplify state drug pricing transparency—from strategic drug price modeling to effortless end-to-end statutory reporting. You’ll learn how our platform supports comprehensive compliance tracking with real-time updates and a built-in compliance calendar, plus proactive legislative monitoring and forecasting to keep [...]

1811, 2025

Making Sense of FMV: Strategies for the Life Sciences Industry

By |November 18th, 2025|Blog|

Introduction Fair Market Value (FMV) remains a central focus within the life sciences industry, as underscored at the recent Pharmaceutical and Medical Device Ethics and Compliance Congress. As the regulatory environment continues to evolve, companies are under increasing scrutiny regarding the appropriateness of compensation paid to healthcare professionals (HCPs). Corporate integrity agreements repeatedly highlight deficiencies [...]

209, 2025

MediSpend and Life Sciences Subsidiary of RLDatix Merge to Form Leading Global Provider of Regulatory and Compliance SaaS Solutions for Life Sciences

By |September 2nd, 2025|News|

New company delivers built-for-purpose, best-in-class solutions spanning the entire product lifecycle for pharmaceutical, biotech, and medical device companies September 02, 2025 - MediSpend and RLDatix Life Sciences, a subsidiary of RLDatix, today announced a definitive agreement to merge, creating a new unified company at the forefront of life sciences innovation and compliance. The new company offers [...]

608, 2025

From Hot Mess to High-Performing: Building a Scalable Third-Party Due Diligence Program

By |August 6th, 2025|Resources|

Does your third-party due diligence process feel more like controlled chaos than a streamlined strategy? In today’s rapidly evolving regulatory landscape, life sciences organizations are struggling to balance comprehensive risk assessments with the need for speed, scale and cross-functional collaboration. In this insightful webinar we’ll guide you through transforming a fragmented third-party risk program [...]

408, 2025

MediSpend Acquires Alucio to Expand AI-Enabled Stakeholder Engagement Capabilities

By |August 4th, 2025|News|

Portsmouth, NH – August 4, 2025 — MediSpend, a global leading provider of compliance and stakeholder engagement solutions for the life sciences industry, announces its acquisition of Alucio, an innovative technology company known for its AI-enabled content management and HCP engagement platform, BEACON. The acquisition enhances MediSpend’s offerings to support more effective scientific exchanges between life [...]

807, 2025

What Life Sciences Companies Need in a Third-Party Due Diligence Platform

By |July 8th, 2025|Blog|

In today’s highly regulated global environment, pharmaceutical, biotech and medical device companies are under increasing pressure to demonstrate compliance across their extended third-party networks. From anti-bribery enforcement to FDA debarment risk to global supply chain integrity, life sciences organizations need more than just spreadsheets and checklists to manage their third-party risk.  A modern SaaS-based third-party [...]

2905, 2025

Italy’s Sunshine Act: Implementation Advances After Three-Year Wait

By |May 29th, 2025|Blog|

After its passage in June 2022, Italy’s Sunshine Act (Law 62/2022) is finally moving toward implementation—marking a significant development in life sciences transparency. The law introduces mandatory reporting obligations for financial relationships between life sciences companies and healthcare professionals (HCPs) or healthcare organizations (HCOs), including transfers of value (ToVs), financial interests, and service agreements. Key [...]

2304, 2025

Strengthening Compliance in Transparency Programs: Key Lessons from Recent DOJ Settlement (Pt. 2)

By |April 23rd, 2025|Blog|

This is Part 2 in our blog series exploring a recent government enforcement action. Haven’t read Part 1 which covers speaker program compliance risks? Be sure to check it out here. Recently, the Department of Justice (DOJ) reached a settlement with a global pharmaceutical company, resolving allegations that one of its subsidiaries paid kickbacks to [...]

2803, 2025

Strengthening Compliance in Speaker Programs: Key Lessons from Recent DOJ Settlement (Pt. 1)

By |March 28th, 2025|Blog|

Since the Office of the Inspector General (OIG) issued its Special Fraud Alert in November 2020, speaker programs have remained under intense regulatory scrutiny. Recently, the Department of Justice (DOJ) reached a settlement with a global pharmaceutical company, resolving allegations that one of its subsidiaries paid kickbacks to healthcare providers (HCPs) to drive prescriptions of [...]

Go to Top